Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity, Reactogenicity and Safety of the Trivalent Influvac 2013/2014 Vaccine
2013-000881-12Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of influenza vaccine in influenza (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Primary immunogenicity endpoint and Reactogenicity and safety. Started Mar 2013; status: completed.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2013-000881-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000881-12.